Sutro Biopharma (STRO) Shares Outstanding (Weighted Average) (2016 - 2025)

Sutro Biopharma has disclosed Shares Outstanding (Weighted Average) across 10 years of filings, most recently posting $8.5 million for Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $8.5 million, up 9.84% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.5 million (up 9.84% YoY), and the FY2025 annual result was $8.5 million, up 9.84% from the prior year.
• Shares Outstanding (Weighted Average) came in at $8.5 million for Q4 2025 at Sutro Biopharma, down from $84.2 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $84.2 million in Q3 2025 to a low of $7.7 million in Q4 2024.
• The 5-year median for Shares Outstanding (Weighted Average) is $54.7 million (2022), against an average of $55.0 million.
• Across the five-year window, Shares Outstanding (Weighted Average) soared 97.89% in 2021 and sank 87.14% in 2024, its largest moves.
• Sutro Biopharma's Shares Outstanding (Weighted Average) stood at $46.1 million in 2021, then increased by 10.02% to $50.7 million in 2022, then climbed by 18.57% to $60.2 million in 2023, then tumbled by 87.14% to $7.7 million in 2024, then advanced by 9.84% to $8.5 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $8.5 million (Q4 2025), $84.2 million (Q3 2025), and $83.8 million (Q2 2025), per Business Quant data.